STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?
Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?
comments(0)
5-min edit window · permanent after that